A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07219212 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG: JNJ-90301900
DRUG: Cisplatin
RADIATION: Intensity Modulated Radiation Therapy (IMRT)

Sponsor

Johnson & Johnson Enterprise Innovation Inc.